Published in N Engl J Med on January 03, 2008
FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer (PaFLO) | NCT01503372
Gastric cancer. Lancet (2009) 7.27
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol (2013) 3.11
A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. Cancer Chemother Pharmacol (2014) 2.26
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol (2010) 2.10
Treatment of gastric cancer. World J Gastroenterol (2014) 1.93
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer (2011) 1.76
Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol (2008) 1.62
Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer (2016) 1.61
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer (2011) 1.58
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer (2010) 1.57
Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy: a multi-institute retrospective study. Gastric Cancer (2011) 1.52
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer (2009) 1.46
Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer. Gastric Cancer (2011) 1.45
Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol (2010) 1.44
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med (2010) 1.43
Gastric cancer: current status of diagnosis and treatment. Cancers (Basel) (2013) 1.42
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer (2010) 1.39
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer (2010) 1.38
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol (2010) 1.37
Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer (2010) 1.36
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer (2009) 1.34
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer (2008) 1.29
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. J Natl Cancer Inst (2013) 1.28
Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver (2013) 1.28
Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer (2009) 1.24
Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer (2010) 1.19
Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer (2011) 1.19
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol (2013) 1.18
Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS One (2011) 1.17
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol (2011) 1.16
Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol (2011) 1.15
A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). Gastric Cancer (2010) 1.13
Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer (2014) 1.12
miR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression. Oncotarget (2016) 1.11
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest New Drugs (2010) 1.10
Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? Oncologist (2012) 1.10
Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer (2014) 1.10
MET amplification as a potential therapeutic target in gastric cancer. Oncotarget (2013) 1.09
Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer (2013) 1.08
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest New Drugs (2011) 1.08
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer (2011) 1.08
Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer (2015) 1.07
Gastric cancer review. J Carcinog (2014) 1.06
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer (2014) 1.05
Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol (2010) 1.05
Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction. J Cancer Res Clin Oncol (2008) 1.05
DNA polymerase η protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy. J Transl Med (2010) 1.04
Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients. Oncologist (2011) 1.04
Peritoneal carcinomatosis. World J Gastroenterol (2013) 1.04
Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. PLoS One (2014) 1.03
Strategies for treating liver metastasis from gastric cancer. Surg Today (2010) 1.02
Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer. Int J Radiat Oncol Biol Phys (2014) 1.02
Treatment options in patients with metastatic gastric cancer: current status and future perspectives. World J Gastroenterol (2014) 1.02
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol (2010) 1.01
New perspectives in the treatment of advanced or metastatic gastric cancer. World J Gastroenterol (2009) 1.01
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer (2008) 1.01
Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer (2014) 1.01
Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer (2009) 1.00
Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer (2014) 1.00
CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer (2011) 1.00
Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer (2011) 1.00
Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol (2015) 1.00
Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs (2010) 0.99
Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer (2012) 0.99
Helicobacter pylori and interleukin-8 in gastric cancer. World J Gastroenterol (2013) 0.99
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs (2009) 0.99
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer (2011) 0.99
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Invest New Drugs (2011) 0.98
Gastric carcinoma in China: Current status and future perspectives (Review). Oncol Lett (2010) 0.98
The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer. BMC Cancer (2012) 0.98
Surgical treatment for patients with Krukenberg tumor of stomach origin: clinical outcome and prognostic factors analysis. PLoS One (2013) 0.98
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget (2015) 0.97
Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol (2008) 0.97
Molecular targeted agents for gastric and gastroesophageal junction cancer. Surg Today (2011) 0.97
Metastatic gastric cancer - focus on targeted therapies. Biologics (2012) 0.96
Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. Gastric Cancer (2012) 0.96
Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report. J Hematol Oncol (2010) 0.95
High expression of RNA-binding motif protein 3 in esophageal and gastric adenocarcinoma correlates with intestinal metaplasia-associated tumours and independently predicts a reduced risk of recurrence and death. Biomark Res (2014) 0.95
Hepatoid adenocarcinoma of the stomach - a different histology for not so different gastric adenocarcinoma: a case report. Int Semin Surg Oncol (2009) 0.95
CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res (2014) 0.95
Palliative resection in noncurative gastric cancer patients. World J Surg (2010) 0.95
GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer (2014) 0.95
A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer. Br J Cancer (2013) 0.94
Gastric cancer and the epoch of immunotherapy approaches. World J Gastroenterol (2015) 0.94
Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. Cancer Immunol Res (2015) 0.94
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs (2013) 0.94
Medical management of gastric cancer: a 2014 update. World J Gastroenterol (2014) 0.94
Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression. Gastric Cancer (2012) 0.94
Chemotherapy for metastatic disease: review from JCOG trials. Int J Clin Oncol (2008) 0.93
Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol (2010) 0.93
Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis. Cancer Res Treat (2010) 0.93
A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Invest New Drugs (2010) 0.93
Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas. J Gastroenterol (2013) 0.93
Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts. Br J Cancer (2011) 0.92
Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. Ther Adv Med Oncol (2013) 0.92
D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy. World J Surg Oncol (2013) 0.92
The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. Gastric Cancer (2016) 0.92
Multimodal treatment of gastric cancer in the west: Where are we going? World J Gastroenterol (2015) 0.92
A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma. World J Gastroenterol (2013) 0.91
Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review. Ther Adv Med Oncol (2015) 0.91
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med (2006) 26.37
Colorectal cancer. Lancet (2010) 8.36
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol (2008) 4.68
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet (2011) 4.36
Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol (2006) 3.24
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol (2013) 3.11
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol (2007) 2.80
Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2009) 2.58
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol (2013) 2.41
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol (2012) 2.33
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol (2010) 1.83
Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet (2002) 1.53
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol (2009) 1.26
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Curr Colorectal Cancer Rep (2013) 1.12
Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol (2011) 1.09
Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol (2012) 1.07
Why faculty must promote their own self-care. Acad Med (2013) 1.06
Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol (2005) 0.99
Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies. Curr Cancer Drug Targets (2010) 0.96
HOX genes in pancreatic development and cancer. JOP (2011) 0.96
The genomic landscape of oesophagogastric junctional adenocarcinoma. J Pathol (2013) 0.95
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunol Immunother (2013) 0.94
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemother Pharmacol (2011) 0.94
Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. Eur J Cancer (2011) 0.91
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC Cancer (2008) 0.88
Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer (2004) 0.88
Reducing the time before consulting with symptoms of lung cancer: a randomised controlled trial in primary care. Br J Gen Pract (2013) 0.88
Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k. Oncologist (2009) 0.87
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. J Thorac Oncol (2010) 0.85
A rare case of a retroperitoneal enterogenous cyst with in-situ adenocarcinoma. World J Surg Oncol (2007) 0.84
Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases. BMC Cancer (2012) 0.83
Pericardial malignant mesothelioma: a latent complication of radiotherapy? Eur J Cardiothorac Surg (2008) 0.83
Pharmacotherapy for oesophagogastric cancer. Drugs (2007) 0.83
Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection. Clin Colorectal Cancer (2012) 0.83
A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. J Clin Oncol (2004) 0.82
Variation in comorbidity and clinical management in patients newly diagnosed with lung cancer in four Scottish centers. J Thorac Oncol (2011) 0.82
Metastatic squamous cell carcinoma of the anus: time for a shift in the treatment paradigm? ISRN Oncol (2012) 0.81
College student stressors: a review of the qualitative research. Stress Health (2012) 0.81
Adjuvant chemotherapy of colorectal cancer. Lancet (2007) 0.81
Improving care for patients with lung cancer in the UK. Thorax (2013) 0.79
Role of erlotinib in the management of pancreatic cancer. Ther Clin Risk Manag (2006) 0.79
Pancreatic neuroendocrine tumors: a review. Future Oncol (2015) 0.78
Metastatic breast cancer presenting as a primary hindgut neuroendocrine tumour. Anticancer Res (2010) 0.78
Trastuzumab for gastric cancer treatment. Lancet (2010) 0.77
Serpin b3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer. J Thorac Oncol (2013) 0.77
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemother Pharmacol (2013) 0.76
Chemotherapy for operable gastric cancer: current perspectives. Indian J Surg Oncol (2012) 0.76
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. BMC Cancer (2004) 0.76
Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design. Health Qual Life Outcomes (2013) 0.75
A comparison between clinical decisions made about lung cancer patients and those inherent in the corresponding Scottish Intercollegiate Guidelines Network (SIGN) guideline. Health Informatics J (2010) 0.75
A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Cancer Chemother Pharmacol (2011) 0.75
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol (2011) 0.75